Vyjuvek by Krystal Biotech: status and timeline

Vyjuvek

Transform DEB treatment by providing redosable wound healing therapy that patients can reapply as needed, improving quality of life.

ScalingStage 5 of 5

Commercial since May 2023. Q2 2026: $119.2M revenue; 730+ payer approvals.

Updated Jun 2026Checked 11 Oct0 updates this week

Milestones

Next · Community dermatology expansion ongoing

FDA approval for recessive and dominant DEB19 May 2023Complete.
Commercial launchMay 2023Complete.
Q2 2026: $119.2M revenue, $965.9M cumulativeJun 2026Complete.
Community dermatology expansion ongoingTarget 2026Current milestone.

Most important updates

Upcoming

2026Community dermatology expansion ongoing (next)
2027International expansion

Current obstacles

Rare disease awarenessDEB affects ~2,000–10,000 U.S. patients. Reaching all eligible patients remains challenging.

Physics limits

Viral vector immunityRepeated topical HSV-1 application could trigger local immune responses.

How it works

3 parts

Gene vector

HSV-1 delivers the gene

Non-replicating herpes simplex virus type 1 carries COL7A1 to wound cells.

Topical application

Applied to wounds

Applied directly to skin wounds; vector transfects cells to produce collagen VII.

Healing

Collagen VII anchors skin

Restored collagen VII stabilizes dermal-epidermal layers, accelerating healing.

Spec sheet

Spec	Vyjuvek
Q2 2026 quarterly revenue	$119.2M^R (reported)
Cumulative revenue since launch	$965.9M^R (reported)
Q1 2026 gross margin	95%^R (reported)
Payer reimbursement approvals	730+^R (reported)

^R reported by the company

Update log

2 updates

Jun 2026

Minor: Vyjuvek Q2 2026 revenue $119.2M; cumulative $965.9M since launchPressCommercial

Fri 19 May 2023

Major: FDA approves Vyjuvek, first redosable gene therapy for dystrophic epidermolysis bullosaPressRegulatory

About Krystal Biotech

The team behind Vyjuvek

Krystal Biotech

Redosable gene therapy, epidermolysis bullosa, topical

Krystal develops redosable topical gene therapies. Vyjuvek, the first redosable gene therapy, treats dystrophic epidermolysis bullosa by delivering COL7A1. Q2 2026 revenue: $119.2M; cumulative $965.9M.

Krystal raised $39.6M in September 2017 IPO; $160M total funding.
Vyjuvek: FDA approved May 2023; Q2 2026 revenue $119.2M with 95% gross margin.
Pipeline: KB407 (CF) in Phase 1 with 2027 registrational study planned; programs in ophthalmology, dermatology, oncology.

krystalbio.com (opens krystalbio.com)Company profile →

Founded: 201511 yrs
Headquarters: United States
Status: Public
Valuation: public
Last round: IPO · $30M20 Sep 2017
Works in: BiotechGene editing & therapy
Coverage: 2 programs · 4 updateslatest 1 Jun 2026checked 11 Oct

Spec

Vyjuvek

Q2 2026 quarterly revenue

$119.2M^R (reported)

Cumulative revenue since launch

$965.9M^R (reported)

Q1 2026 gross margin

95%^R (reported)

Payer reimbursement approvals

730+^R (reported)